Fanconi anemia complementation group D1
Fanconi anemia complementation group D1
Explore linked clinical trials. Standard reference: MONDO:00115847 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fanconi anemia complementation group D1, Fanconi anemia complementation group N, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, central nervous system malformation, hereditary disease, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, male reproductive organ cancer, male reproductive system disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-09-17 | NCT04038502 | |
| Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer | Fanconi anemia complementation group D1, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-09-15 | NCT07821229 | |
| Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies | Fanconi anemia complementation group D1, Fanconi anemia complementation group N, microphthalmia, syndromic 9 | Recruiting | Phase 1 | 2026-09-02 | NCT06458712 | |
| Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC | Digestive System Diseases, Digestive System Neoplasms, Fanconi anemia complementation group D1, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 2 | 2026-08-14 | NCT07765836 | |
| FaCT Trial (Facilitated Cascade Testing Trial) | Fanconi anemia complementation group D1 | Active, not recruiting | Not applicable | 2026-06-30 | NCT04613440 | |
| Olaparib In Metastatic Breast Cancer | Fanconi anemia complementation group D1, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-01-05 | NCT03344965 | |
| Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | Fanconi anemia complementation group D1, Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2025-03-20 | NCT05485766 |